China now accepting clinical trial data from other countries

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/eyegelb)
(Image: iStock/eyegelb)

Related tags: Clinical trial, Pharmacology, Good clinical practice, Us

China has announced that it will now accept clinical trial data from other countries in a new guideline that aims to reform the management of clinical trials.

The new guideline​ was issued (in Chinese) by the General Office of the Communist Party of China Central Committee and the General Office of the State Council earlier this week.

According to a post by the State Council, the guideline aims to promote “the adjustment of industrial structure and technological innovation in the sector of drugs and medical devices, improving industrial competitiveness, and meeting the public’s clinical needs​.”

Management of clinical trials will be reformed through record-filing management of clinical trial institutes, encouraging social forces to invest in clinical trial institutes, and supporting medical organizations, research institutes and colleges to conduct clinical trials​,” according to the post.

A draft​ of the new policies was released earlier this year at which time Philip Gregory, managing director at George Clinical told us​ if implemented, the changes would “standardize regulatory requirements, allow for greater use of foreign data broadening eligibility of sites to conduct trials, provide greater transparency of the ethics process, and ultimately shorten approval times​.”

The China Food and Drug Administration (CFDA) did not respond to a request for comment

The FDA's position

The FDA accepts clinical data from studies conducted at sites outside of the US for products manufactured in the US and imported into the country.

The designs of trials carried out in the US and elsewhere are generally similar, following specifications in US regulations and guidance as well as advice in documents developed under the auspices of the ICH, and transmitted to sponsors during drug development,”​ an FDA spokesperson told us.

However, studies must be conducted in accordance with accepted ethical standards and good clinical practices (GCPs), which are outlined in US and international regulations and guidance.

As described in FDA guidance, a sponsor of a marketing application should explain how foreign clinical data are applicable to the US population and US medical practice​,” the spokesperson added.

Strengthening clinical trial operations

The CFDA has made several changes over the past year as the agency “is trying its best to strengthen clinical trial operations​,” Rong Zhang, MS, deputy chief technician at the CFDA said​ in June at the DIA Annual Meeting.

As part of this, the agency also recently announced membership in the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Additionally, a Marketing Authorization Holder (MAH) program​ is being piloted across ten provinces and municipalities in China. “The pilot allows more stakeholders to be a part of pharmaceutical development​,” an US Food and Drug Administration (FDA) spokesperson told us in July.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Related suppliers

Follow us

Products

View more

Webinars